Positive Phase III data herald a significant turnaround in the fortunes of GlaxoSmithKline’s (LSE: GSK) coronavirus program.
Data monitors have recommended halting the COMET-ICE study due to strong efficacy, with an 85% reduction in hospitalization or death in people receiving VIR-7831 as monotherapy, compared to placebo.
Together with Vir Biotechnology (Nasdaq: VIR), GSK is testing the monoclonal antibody as an early treatment for COVID-19 in adults at high risk of hospitalization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze